In this sense, Fittall et al. 54 reported recurrent rearrangement of FOS only in osteoblastoma benign tumors and not in other malignant bone tumors, concluding that in clinic FOS may be genetically altered only in benign bone tumors. This evidence concerns the gene FOS and bone benign neoplasm.